Search

News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’

The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.

Source: Chronic Heart Failure and Lipidology 9. 3. 2020

News Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor

The current publication of the long-term extension of the UNCOVER-3 study, which focused on the treatment of psoriasis with ixekizumab, describes the efficacy and safety of 4 years of use of this drug.

Source: Biological Treatment 13. 4. 2021

News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease

Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?

Source: Heart Failure 20. 8. 2021

Články časopisu Education in schizophrenia: How patients and their relatives assess the relapse prevention programme PREDUKA

Author of the article: Lucie Bankovská Motlová, Eva Dragomirecká, Šárka Matelová, Renata Otevřelová, Radka Čermáková, Jan Čermák, Eva Lednická, Renata Hegedüšová, Tomáš Hübsch, Soňa Rothanzlová, Martinatomešová, Filip Španiel, Eva Kitzlerová Source: Časopis lékařů českých | 1/2010 1. 1. 2010

News Perioperative Thromboprophylaxis in Elderly Patients

Thromboembolic disease (TED) is among the most common causes of death in hospitalized patients and also constitutes a significant portion of complications following surgical procedures. Without prophylaxis, thrombosis would develop in the perioperative period in almost 25% of patients. The risk of TED significantly increases with age, as does mortality. Over 21% of thrombotic complications occur in individuals over 65 years of age, and up to 16% of patients over 80 years old die shortly after being diagnosed with TED. It is crucial to focus on appropriate prevention and prophylaxis of TED in geriatric patients. However, studies have shown that thromboprophylaxis in hospitals in Europe and the USA is inadequate. Reasons may include concerns about increased bleeding during surgical procedures.

Source: Thromboprophylaxis 29. 4. 2021

News Screenings of Lung Cancer and COPD are Significant. What Do the Latest Data from Czechia Say?

At the end of January, an expert seminar was held, focusing on updates in the treatment of respiratory diseases. During this event, the head of the Pulmonary Clinic at LF UK and FN Hradec Králové, Associate Professor MUDr. Vladimír Koblížek, Ph.D., gave a lecture on the current Czech findings from lung cancer screenings and a project aimed at the early detection of chronic obstructive pulmonary disease (COPD).

Source: Cough Therapy 12. 4. 2023

News Pediatric Immune Thrombocytopenia Does Not Overlap with Adult ITP

Immune thrombocytopenia (ITP) is a highly heterogeneous disease characterized by various bleeding manifestations and different needs for treatment or likelihood of remission. The difference is accentuated in terms of the disease course between children and adult patients.

Source: Immune Thrombocytopenia 8. 6. 2020

News FEIBA in Real Clinical Practice –⁠ Fresh Data from the Observational Study FEIBA GO

FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.

Source: Hemophilia 27. 11. 2023

News COVID-19 and Immune Thrombocytopenic Purpura −⁠ Spanish Experience Suggests Surprising Connections

In a retrospective study examining the impact of COVID-19 on immune thrombocytopenic purpura, Spanish authors surprisingly observed a paradoxical effect.

Source: Immune Thrombocytopenia 2. 11. 2020

News Improving Physical Function in Patients with COPD in Routine Clinical Practice

The increase in exercise capacity with the use of a fixed-dose combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies in patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefits in real-world practice and also focused on patient satisfaction with the inhaler.

Source: COPD 9. 11. 2020

News What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?

Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia, vitiligo, celiac disease, and idiopathic inflammatory bowel diseases –⁠ these are comorbidities that often trouble patients with atopic dermatitis (AD). Modern systemic treatments bring new hope to these patients. "The primary benefit of targeted treatment, especially for severe AD, is the mitigation or elimination of chronic inflammation and persistent itching, significantly improving the quality of life for patients," says Chief Physician MUDr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology of MU and St. Anne's University Hospital in Brno.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 26. 6. 2023

News Does Beta-Blocker Therapy Reduce the Cardiovascular Benefit of Aerobic Exercise in Patients with Arterial Hypertension?

Regular aerobic exercise is generally recommended for patients suffering from arterial hypertension to reduce blood pressure values, improve physical fitness, and other parameters. The intensity of exercise is most often derived from the target heart rate, which is pharmacologically influenced in patients on beta-blockers. The question, therefore, is whether aerobic exercise brings the same cardiovascular benefit to this group of patients as it does to those not taking beta-blockers.

Source: Cardiovascular Continuum 5. 4. 2021

News Do Gliflozins Affect the Need to Use Diuretics?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.

Source: Heart Failure 1. 10. 2023

News Prevalence and Incidence of Age-Related Macular Degeneration in Europe –⁠ Current Overview and Trend Analysis

A comprehensive review article by authors from Bonn, Germany, published late last year in the British Journal of Ophthalmology, provides current data and estimates of the incidence and prevalence of age-related macular degeneration in Europe. Here is a brief summary of the key findings from this latest analysis.

Source: Glaucoma 6. 2. 2020

News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?

In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.

Source: Anticoagulant Treatment 6. 5. 2021